GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Accumulated Depreciation

Contineum Therapeutics (Contineum Therapeutics) Accumulated Depreciation : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Contineum Therapeutics's quarterly accumulated depreciation increased from Sep. 2023 ($-1.44 Mil) to Dec. 2023 ($-1.48 Mil) but then stayed the same from Dec. 2023 ($-1.48 Mil) to Mar. 2024 ($0.00 Mil).

Contineum Therapeutics's annual accumulated depreciation increased from Dec. 2021 ($-0.96 Mil) to Dec. 2022 ($-1.28 Mil) and increased from Dec. 2022 ($-1.28 Mil) to Dec. 2023 ($-1.48 Mil).

Contineum Therapeutics Accumulated Depreciation Historical Data

The historical data trend for Contineum Therapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Accumulated Depreciation Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Accumulated Depreciation
-0.96 -1.28 -1.48

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Accumulated Depreciation Get a 7-Day Free Trial -1.28 - -1.44 -1.48 -

Contineum Therapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Contineum Therapeutics Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Accumulated Depreciation
Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Website
https://www.contineum-tx.com
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024